MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options and PDMR dealing
ROCKVILLE, MD, August 29, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 26 August 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 3,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 3,000 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by John Johnston at a price range between $4.230 and $4.350 per Common Stock ("Sale"). The sold shares represent approximately 0.9% of John Johnston's total equity and option holdings in the Company's stock capital, respectively.
Following the Exercise and Sale, John Johnston holds 120,583 shares of Common Stock representing 0.1% of the issued stock capital of the Company. Following the Exercise, John Johnston holds a further 186,918 options over Common Stock and 21,367 restricted stock units.
The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by John Johnston on 19 December 2023 relating solely to the sale of shares acquired from exercise of options that expire on 14 July 2027.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400
|
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
|
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700
|
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical, and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| John Johnston | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Non-Executive Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte, Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Exercise of Options over common stock | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Exercise Price(s) | Volume(s) | | |
| | | $2.926 | 3,000 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 3,000 | ||||
| | | ||||
| - Price | $2.926 | ||||
| | | ||||
| e)
| Date of the transaction
| 26 August 2024 | |||
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |||
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| John Johnston | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Non-Executive Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| MaxCyte, Inc. | |||
| b)
| LEI
| 54930053YHXULRFCU991 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Common Stock of $0.01 each | |||
| | | ||||
| Identification code | US57777K1060 | ||||
| | | ||||
| b)
| Nature of the transaction
| Sale of common stock | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Exercise Price(s) | Volume(s) | | |
| | | $4.2300 | 400 | | |
| | | $4.2500 | 300 | | |
| | | $4.2550 | 400 | | |
| | | $4.2650 | 58 | | |
| | | $4.2700 | 301 | | |
| | | $4.2800 | 152 | | |
| | | $4.2900 | 87 | | |
| | | $4.3000 | 600 | | |
| | | $4.3100 | 296 | | |
| | | $4.3200 | 206 | | |
| | | $4.3500 | 200 | | |
| | | | | | |
| d)
| Aggregated information | | |||
| | | ||||
| - Aggregated volume | 3,000 | ||||
| | | ||||
| - Price | $4.2804 | ||||
| | | ||||
| e)
| Date of the transaction
| 26 August 2024 | |||
| f)
| Place of the transaction
| US Stock Exchange, Nasdaq | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.